TriSalus (TLSI) Insider Award: 15K Stock Options to Director Wahlstrom

Rhea-AI Filing Summary

Form 4 Overview – TriSalus Life Sciences, Inc. (TLSI)

Director Mats Wahlstrom reported an acquisition of derivative securities on 12 June 2025. The filing records a grant of 15,000 non-qualified stock options (‘Director Stock Option – right to buy’) with an exercise price of $5.50 per share. These options will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, contingent upon continued board service.

Following this grant, Mr. Wahlstrom now holds a total of 200,945 derivative securities (options) in a direct ownership capacity. No common shares were bought or sold, and no cash consideration exchanged hands at the time of the grant. The option’s expiration date is 11 June 2035, providing a 10-year exercise window once vested.

This transaction represents routine director compensation and does not alter the company’s outstanding share count or cash position. It signals continued alignment of the director’s incentives with shareholder returns but is not expected to have a material impact on TLSI’s near-term financials or market valuation.

Insights

Financial Analyst

TL;DR: Routine director option grant; aligns incentives but negligible financial impact or dilution.

The filing discloses a standard equity compensation award—15,000 options at $5.50—to director Mats Wahlstrom. No shares were sold, and the strike price sits above the current exercise timeline, so immediate dilution is nil. Beneficial ownership rises to 200,945 options, underscoring long-term alignment with shareholders. Given TriSalus’s micro-cap status, the award is small relative to total shares outstanding and lacks short-term balance-sheet consequences. Investors should view the grant as neutral: it neither signals insider conviction via open-market buying nor insider pessimism via selling. Impact on valuation, liquidity, or control dynamics is de minimis.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wahlstrom Mats

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 200,945 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wahlstrom Mats

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.5	06/12/2025		A		15,000		(1)	06/11/2035	Common Stock	15,000	$0	200,945	D

Explanation of Responses:

1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TLSI disclose in the latest Form 4 filing?

TLSI reported a grant of 15,000 stock options to director Mats Wahlstrom on 06/12/2025 at an exercise price of $5.50.

How many TLSI options does director Mats Wahlstrom own after the transaction?

After the grant, Wahlstrom beneficially owns 200,945 derivative securities (stock options) directly.

When will the newly granted TLSI options vest?

The options will fully vest on the one-year anniversary of 06/12/2025 or on the date of the next annual shareholder meeting, whichever comes first.

Is this Form 4 filing considered a purchase or sale of TLSI common shares?

No. It documents an equity award; no common shares were bought or sold.

Does the option grant immediately dilute existing TLSI shareholders?

No. Dilution occurs only if the options are exercised; immediate dilution is null.

What is the expiration date of the granted TLSI options?

The options expire on 06/11/2035, providing a ten-year exercise window.